Evaluation of miR-711 as Novel Biomarker in Prostate Cancer Progression

Document Type : Research Articles


1 Molecular and Cell Biology, Department of Biochemistry, King George’s Medical University, Lucknow, U.P, India.

2 Department of Urology, King George’s Medical University, Lucknow, U.P, India.

3 Division of Endocrinology, CSIR-Centre Drug Research Institute, Lucknow, U.P, India.

4 Department of Zoology, Lucknow University, Lucknow, U.P, India.

5 5Environmental Carcinogenesis, CSIR-IITR, Lucknow, U.P, India.


Objective: MicroRNAs (miRs) are class of small non-coding regulatory RNA aberrantly expressed in various types of malignancies including prostate cancer and serves as potential targets to develop new diagnostic and therapeutic strategies. In this quiet we investigated miRNAs expression profile in benign prostatic hyperplasia (BPH) and prostate cancer (PCa) tissue samples and correlated their expression with clinicopathological parameters. Methodology: The miRNAs expression profile as well as their validation has been done by using Microarray and RT-PCR, respectively. Additionally, we also tried to speculate microRNA-mRNA regulatory module through computational target predictions by using Targetscan, Miranda and MirWalk and obtained results were analysed through DAVID software. Result: We observed that miR-711 is significantly deregulated in BPH and PCa, compared to controls. The lower expression of miR-711 was found to be significantly associated with high Gleason score and metastatic disease. Furthermore, the computational target prediction analysis explored miR-711 association to various cancer cells signalling cascade key molecules associated with cancer cell survival.Conclusion: From our observations we suggest that miR-711 may play a critical role in PCa progression, regulation of various cancer cell survival signalling cascades and that it may be a valuable biomarker for prediction of metastatic disease and poor prognosis in PCa.


Main Subjects

Volume 18, Issue 8
August 2017
Pages 2185-2191
  • Receive Date: 26 April 2017
  • Revise Date: 23 July 2017
  • Accept Date: 11 August 2017
  • First Publish Date: 11 August 2017